New Research Raises Kidney Concerns for Widely Used Cholesterol Medication

Statins are globally prescribed to reduce cholesterol and protect the heart, with Rosuvastatin considered one of the most effective options. However, recent research has drawn attention to its potential impact on kidney health, raising concerns for long-term users.

Researchers at Johns Hopkins University in the United States conducted a comprehensive study to examine the effects of Rosuvastatin on renal function. Early trials during FDA approval had already flagged signs such as blood and protein in urine among some patients, suggesting possible kidney stress, but large-scale long-term studies were limited until now.

The new study analyzed health records of over nine lakh individuals, including approximately 1.5 lakh taking Rosuvastatin and nearly eight lakh on Atorvastatin, another widely used statin. Kidney health was monitored over three years, and the results were notable. Among Rosuvastatin users, around 2.9 percent showed hematuria, or blood in the urine, and one percent had proteinuria, significantly higher than in the Atorvastatin group.

The study also highlighted risks associated with Rosuvastatin dosage. Patients taking higher doses faced an increased likelihood of kidney complications, including severe kidney failure requiring dialysis or transplantation. Additionally, patients with pre-existing kidney conditions were often prescribed high doses, contrary to FDA guidance.

Interestingly, both Rosuvastatin and Atorvastatin were found to be equally effective in protecting the heart and reducing risks of heart attack and stroke. This suggests that patients at risk of kidney issues may safely consider switching medications under medical guidance without compromising cardiovascular benefits.

Medical experts stress that this research is intended to inform awareness and encourage consultations with doctors. Patients should not make changes to their prescriptions without professional advice. Regular monitoring of kidney function is recommended for anyone taking long-term statin therapy, particularly Rosuvastatin.

This study underscores the importance of balancing cardiovascular benefits with kidney safety, prompting patients and physicians to carefully evaluate statin choices and dosages.